Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18237895 | 0.76 | CRBN (0.34) | CRBN | |
| SCHEMBL19153767 | 0.73 | PDPK1 (0.36) | CRBNPDPK1 | |
| SCHEMBL19153334 | 0.68 | CRBN (0.39) | CRBNPDPK1 | |
| SCHEMBL19153943 | 0.65 | MMP12 (0.38) | — | |
| SCHEMBL19153341 | 0.64 | MAPT (0.32) | PDPK1 | |
| Succinimide SCHEMBL774 | 0.60 | — | — | |
| Succinimide SCHEMBL1466558 | 0.60 | — | — | |
| Succinimide SCHEMBL1326078 | 0.60 | CRBN (1.00) | CRBNKDM4E | |
| Succinimide SCHEMBL8361206 | 0.60 | CRBN (1.00) | CRBNKDM4E | |
| Succinimide SCHEMBL1600526 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | CRBN 1246/4885PDPK1 2826/4885KDM4E 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.